aTYR PHARMA INC Retained Earnings
aTYR PHARMA INC (ATYR) had Retained Earnings of -$627.26 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-07
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$627.26M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$616.96M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$606.16M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$592.20M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$627.26M 10-Q · filed 2026-08-07 |
| 2026-03-31 | -$616.96M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$606.16M 10-Q · filed 2026-08-07 |
| 2025-09-30 | -$592.20M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$566.46M 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$546.93M 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$532.05M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$517.08M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$499.82M 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$483.51M 10-Q · filed 2024-05-02 |
| 2023-12-31 | -$468.02M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$453.26M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$441.92M 10-Q · filed 2023-08-09 |
| 2023-03-31 | -$429.58M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$417.63M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$410.11M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$396.87M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$384.45M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$372.30M 10-K · filed 2023-03-14 |
| 2021-09-30 | -$363.74M 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$356.07M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$345.68M 10-Q · filed 2021-05-14 |
| 2020-12-31 | -$338.53M 10-K · filed 2022-03-15 |
| 2020-09-30 | -$333.60M 10-Q · filed 2020-11-13 |
| 2020-06-30 | -$327.00M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$320.55M 10-Q · filed 2020-05-12 |
| 2019-12-31 | -$322.30M 10-K · filed 2021-03-24 |
| 2019-09-30 | -$316.33M 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$310.69M 10-Q · filed 2019-08-14 |
| 2019-03-31 | -$304.84M 10-Q · filed 2019-05-14 |
| 2018-12-31 | -$298.70M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$292.38M 10-Q · filed 2018-11-14 |
| 2018-06-30 | -$285.26M 10-Q · filed 2018-08-14 |
| 2018-03-31 | -$274.85M 10-Q · filed 2018-05-15 |
| 2017-12-31 | -$264.19M 10-K · filed 2019-03-26 |
| 2017-09-30 | -$252.71M 10-Q · filed 2017-11-14 |
| 2017-06-30 | -$241.52M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$229.38M 10-Q · filed 2017-05-11 |
| 2016-12-31 | -$215.98M 10-K · filed 2018-03-20 |
| 2016-09-30 | -$203.41M 10-Q · filed 2016-11-14 |
| 2016-06-30 | -$189.59M 10-Q · filed 2016-08-10 |
| 2016-03-31 | -$174.21M 10-Q · filed 2016-05-11 |
| 2015-12-31 | -$158.12M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$141.63M 10-Q · filed 2015-11-10 |
| 2015-06-30 | -$130.30M 10-Q · filed 2015-08-12 |
| 2015-03-31 | -$119.22M 10-Q · filed 2015-06-18 |
| 2014-12-31 | -$110.15M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |